Celgene Presents Interim Results From Cancer Drug Study
Zacks Investment Research | Jun 18, 2017 11:01PM ET
Celgene Corporation (NASDAQ:CELG) announced encouraging results from an interim analysis of a phase IIIb study, MAGNIFY, on Revlimid.
The study evaluated Revlimid in combination with Roche Holding (SIX:ROG) AG’s (OTC:RHHBY) Rituxan (R2) in patients with relapsed or refractory marginal zone lymphoma (MZL). The results were presented at nternational Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.
The study continues to show promising results and tolerable safety profile in indolent lymphomas particularly in difficult-to-treat patient subsets.
Shares of Celgene have outperformed the Zacks classified Medical-Biomedical and Genetics industry year to date. Specifically, the stock gained 5.8% during this period, compared with a gain of 2% for the industry.
Celegene’s key growth driver, Revlimid is an oral immunomodulatory drug ad is currently approved for several indications including multiple myeloma (MM), myelodysplastic syndromes (MDS) and mantle cell lymphoma (MCL).
The MAGNIFY study evaluates the clinical activity of 12 cycles of R2 combination therapy followed by randomization to either 18 cycles of R2 maintenance or 18 cycles of Rituxan monotherapy, in patients with relapsed or refractory follicular lymphoma (FL), MZL or MCL. The primary endpoint in the study is progression-free survival (PFS). As of Jan 9, 2017, the PFS for all FL patients was 70%, and evaluable FL patients had overall response rate (ORR) of 66% which was the secondary endpoint.
Data at IMCL also focused on patients with MZL. After 13.8 months of initiation of therapy with the R2 combination, evaluable patients with MZL (n=32) achieved an ORR of 66%.
The most common grade 3 or 4 adverse events observed in patients with MZL were neutropenia (32%), thrombocytopenia (16%) and leukopenia (11%).
REVLIMID was granted Orphan Drug Designation for the treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in April 2015.
Celgene Corporation Price and Consensus
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.